| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5061703 | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(9 years ago) | |
|
US5061703 (Pediatric) | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(8 years ago) | |
| US8329752 | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 7 months from now) | |
| US8362085 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 7 months from now) | |
| US8283379 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 7 months from now) | |
| US8173708 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 7 months from now) | |
| US8168209 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 7 months from now) | |
| US8598233 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 7 months from now) | |
|
US8362085 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8173708 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8283379 (Pediatric) | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
May, 2026
(2 years from now) | |
|
US8329752 (Pediatric) | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8168209 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8598233 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
| US8039009 | ABBVIE | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(4 years from now) | |
|
US8039009 (Pediatric) | ABBVIE | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(5 years from now) | |
Namenda Xr is owned by Abbvie.
Namenda Xr contains Memantine Hydrochloride.
Namenda Xr has a total of 16 drug patents out of which 2 drug patents have expired.
Expired drug patents of Namenda Xr are:
- US5061703
- US5061703*PED
Namenda Xr was authorised for market use on 21 June, 2010.
Namenda Xr is available in capsule, extended release;oral dosage forms.
Namenda Xr can be used as treatment of moderate to severe dementia of the alzheimer's type.
The generics of Namenda Xr are possible to be released after 24 September, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-138) | Jul 03, 2017 |
| Pediatric Exclusivity(PED) | Jan 03, 2018 |
| New Dosage Form(NDF) | Jun 21, 2013 |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 June, 2010
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
NAMENDA XR family patents
